0
0
April 7, 2026
A landmark meta-analysis of 64 clinical trials has confirmed that popular GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic) and dulaglutide (Trulicity), deliver remarkably consistent weight loss benefits regardless of a patient’s age, race, ethnicity, or starting body mass index (BMI). However, the study uncovered one notable outlier: biological sex. While the drugs are highly effective for both groups, women experience modestly greater weight loss results than men.
The findings, published online March 2, 2026, in JAMA Internal Medicine, represent one of the most comprehensive looks at how these “blockbuster” medications perform across diverse populations. Led by researchers at the Johns Hopkins Bloomberg School of Public Health, the team analyzed data from tens of thousands of participants across 41 published articles through mid-2024, providing much-needed clarity for clinicians and patients navigating the surging demand for obesity treatments.
Universal Efficacy Across Demographics
For years, a central question has loomed over the rapid rise of GLP-1 RAs: Do they work equally well for everyone? This is particularly critical given that obesity disproportionately affects Black and Hispanic communities in the United States, and older adults often respond differently to metabolic medications.
The researchers analyzed 64 trials, including specific subgroups to test these variables. Seven trials involving 4,314 patients assessed age differences, while others looked at race and baseline blood sugar levels (HbA1c). The results were strikingly uniform. Whether a patient was under 65 or over 65, or whether they identified as White, Black, Asian, or Hispanic, the weight loss percentages remained steady. Similarly, starting BMI or initial blood sugar levels did not significantly handicap the drug’s effectiveness.
“These results should give clinicians and their patients more confidence that GLP-1 RAs work similarly well across different racial and ethnic populations, and different ages and weights,” said senior author Hemal Mehta, MD, PhD, associate professor of epidemiology at Johns Hopkins Bloomberg School of Public Health.
The “Sex Gap” in Weight Loss
While the drugs proved to be “equal opportunity” across most categories, a clear trend emerged between men and women. The analysis of six trials covering 19,906 patients revealed that women lost an average of 10.88% of their initial body weight, compared to 6.78% for men.
This 4% absolute difference is statistically significant, though researchers emphasize that a 7% weight loss in men is still clinically meaningful for reducing the risk of chronic diseases like type 2 diabetes and hypertension.
Experts hypothesize that several factors may contribute to this gap:
-
Hormonal Synergy: Estrogen may interact with GLP-1 receptors to enhance the drug’s appetite-suppressing effects.
-
Pharmacokinetics: Variations in how male and female bodies metabolize the drugs.
-
Baseline Weight: In many clinical trials, female participants tend to have lower starting weights or different body compositions than their male counterparts.
“This meta-analysis is reassuring for broad applicability, but the sex difference warrants further investigation into pharmacokinetics and hormones like estrogen,” noted Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, who was not involved in the study.
How GLP-1 Drugs Transform Metabolism
GLP-1 receptor agonists work by mimicking a natural gut hormone called glucagon-like peptide-1. When we eat, this hormone signals the brain to feel full and prompts the pancreas to release insulin. By staying in the system longer than the natural hormone, drugs like semaglutide slow gastric emptying and significantly reduce calorie intake.
Beyond weight loss, these medications have been shown to reduce the risk of heart attacks and strokes. While semaglutide and dulaglutide were the primary focus of this study, it is important to note that the researchers excluded tirzepatide (Zepbound/Mounjaro) from this specific analysis because it targets two hormones (GLP-1 and GIP) rather than just one.
Public Health and Access
The findings have major implications for public health equity. With obesity affecting approximately 42% of U.S. adults, the confirmation that these drugs work effectively across all races and ethnicities supports more inclusive prescribing practices.
“The popularity and the cost of GLP-1 RAs are such that we need more studies like this to better understand the benefits… especially for individuals that might be under-represented in clinical trials,” said corresponding author G. Caleb Alexander, MD, MS, a professor of epidemiology at Johns Hopkins.
In practical terms, for a person weighing 250 pounds, a 10% weight loss translates to 25 pounds—a threshold that medical experts say is sufficient to “reset” metabolic health and significantly lower the risk of cardiovascular events.
Limitations and Future Outlook
Despite the robust nature of the meta-analysis, there are limitations. The data includes trials only through mid-2024 and may not reflect real-world “adherence” issues, where patients might stop taking the medication due to side effects or cost.
Furthermore, clinical trials often enroll volunteers who are generally healthier than the average patient with multiple comorbidities. There are also ongoing concerns regarding “muscle wasting” and long-term gastrointestinal side effects, particularly in the elderly population.
As the medical community moves toward personalized medicine, future research may focus on tailoring dosages based on genetic markers or sex. For now, the message for the general public is one of optimism: the tools to manage obesity are proving to be effective for a broad and diverse range of the population.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.medscape.com/viewarticle/glp-1-weight-loss-holds-across-race-age-bmi-not-sex-2026a1000afg?form=fpf
